WO2024254522A3 - Formulations liquides d'épinéphrine - Google Patents

Formulations liquides d'épinéphrine Download PDF

Info

Publication number
WO2024254522A3
WO2024254522A3 PCT/US2024/033103 US2024033103W WO2024254522A3 WO 2024254522 A3 WO2024254522 A3 WO 2024254522A3 US 2024033103 W US2024033103 W US 2024033103W WO 2024254522 A3 WO2024254522 A3 WO 2024254522A3
Authority
WO
WIPO (PCT)
Prior art keywords
epinephrine
liquid formulations
pharmaceutically acceptable
acceptable salt
liquid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033103
Other languages
English (en)
Other versions
WO2024254522A2 (fr
Inventor
Arunya Usayapant
Chaoju Xiao
Christopher Kegan CALA
Jennifer GEHLE-NOVAK
Jessica ROZEMBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi USA LLC
Original Assignee
Fresenius Kabi USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi USA LLC filed Critical Fresenius Kabi USA LLC
Publication of WO2024254522A2 publication Critical patent/WO2024254522A2/fr
Publication of WO2024254522A3 publication Critical patent/WO2024254522A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une formulation liquide comprenant de l'épinéphrine ou un sel pharmaceutiquement acceptable de celle-ci. La formulation selon l'invention comprend de l'acide ascorbique et/ou un sel pharmaceutiquement acceptable de celui-ci, un agent d'isotonicité, et a un pH d'environ 3,0 à 5,0. La formulation liquide selon l'invention est stable et prête à être administrée.
PCT/US2024/033103 2023-06-07 2024-06-07 Formulations liquides d'épinéphrine Ceased WO2024254522A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506780P 2023-06-07 2023-06-07
US63/506,780 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254522A2 WO2024254522A2 (fr) 2024-12-12
WO2024254522A3 true WO2024254522A3 (fr) 2025-05-15

Family

ID=93796410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033103 Ceased WO2024254522A2 (fr) 2023-06-07 2024-06-07 Formulations liquides d'épinéphrine

Country Status (1)

Country Link
WO (1) WO2024254522A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189352A1 (en) * 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US20190269782A1 (en) * 2018-02-06 2019-09-05 Ars Pharmaceuticals Inc. Intranasal epinephrine formulations and methods for the treatment of disease
US20200230079A1 (en) * 2017-01-30 2020-07-23 Nevakar Inc. Norepinephrine compositions and methods therefor
US20200268689A1 (en) * 2017-09-26 2020-08-27 Ys Pharmtech Stabilization of epinephrine formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189352A1 (en) * 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US20200230079A1 (en) * 2017-01-30 2020-07-23 Nevakar Inc. Norepinephrine compositions and methods therefor
US20200268689A1 (en) * 2017-09-26 2020-08-27 Ys Pharmtech Stabilization of epinephrine formulations
US20190269782A1 (en) * 2018-02-06 2019-09-05 Ars Pharmaceuticals Inc. Intranasal epinephrine formulations and methods for the treatment of disease

Also Published As

Publication number Publication date
WO2024254522A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
AU2746695A (en) Metalloproteinase inhibitors
CA2411754A1 (fr) Acide 4-¬(4-chloro-2-hydroxybenzoyl)amino|butanoique et compositions d'administration d'agents actifs
ATE157867T1 (de) Geschmacksmaskierende zusammensetzungen von ranitidin
WO2003000343A3 (fr) Administration d'inhibiteurs de phosphodiesterase destinee au traitement de l'ejaculation precoce
KR20060032657A (ko) 스프레이 가능한 창상 데브리더
IL114193A0 (en) Ophthalmic pharmaceutical compositions
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
HUP0102250A2 (hu) Nemstabilis dipeptidilpeptidáz IV-gátlók vegyületei, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
NO20004721L (no) Bruseformuleringer
ATE549015T1 (de) Pharmazeutische wirkstoffhaltige formulierung mit überzug
YU3101A (sh) Farmaceutska formulacija suspenzije koja obuhvata amoksicilin, klavulonsku kiselinu i celulozu
US4269835A (en) Nasal composition for relieving nasal distress
UA74347C2 (uk) Безводна або майже безводна, стабільна рідка композиція
DK0727996T3 (da) Fendazolformuleringer
DK0693926T3 (da) Ny farmaceutisk sammensætning til fremstilling af et stabilt pulver indeholdende en kombination af acetylsalicylsyre og metoclopramid som aktiv bestanddel.
WO2024254522A3 (fr) Formulations liquides d'épinéphrine
ES2060147T3 (es) Nuevas emulsiones acuosas concentradas, su procedimiento de preparacion y su aplicacion en el campo plaguicida.
AU2002329042A1 (en) Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
CA2420640A1 (fr) Preparations combinees de derives d'acide 3-n-formyl- hydroxyamino-propylphosphonique ou de derives d'acide 3-n- acethyl-hydroxyamino-propylphosphonique avec ingredients speciaux pharmaceutiquement actifs
AU7470098A (en) Antithrombotic agents
JOP20230297A1 (ar) تركيبة مُعَلَّق مائي توخذ عن طريق الفم تشتمل على مُركَّب كاربامات
DK1019037T3 (da) Lægemiddel indeholdende delta-aminolevulinsyre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820178

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202517132872

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2024820178

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202517132872

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2024820178

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820178

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820178

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024820178

Country of ref document: EP

Effective date: 20260107

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24820178

Country of ref document: EP

Kind code of ref document: A2